XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔
H
H

Hikma


خبر

Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug

Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug By Mike Scarcella Aug 27 (Reuters) - Drug companies Jazz JAZZ.O and Hikma HIK.L must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy drug Xyrem, causing health plans to pay higher prices, a U.S. judge in California has ruled. U.S. District Judge Richard Seeborg’s ruling on Monday night in San Francisco cleared a path to trial on some claims in the long-running multidistrict legal act
H

Danske Bank, Lotus Bakeries NV, Vesuvius

EUROPE RESEARCH ROUNDUP-Danske Bank, Lotus Bakeries NV, Vesuvius Aug 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Danske Bank, Lotus Bakeries NV and Vesuvius, on Tuesday. HIGHLIGHTS * Abrdn Plc ABDN.L : Morgan Stanley raises target price to 160p from 149p * Danske Bank DANSKE.CO : Morgan Stanley initiates coverage with overweight rating * Lotus Bakeries NV LOTB.BR : Berenberg raises target price to EUR 10,300 from EUR 9,000 *
A
A
A
B
C
D
E
F
H
H
K
L
M
M
N
O
S
S
S
S
S
H
A
S
U

Ashtead Group, Beazley, Entain

EUROPE RESEARCH ROUNDUP-Ashtead Group, Beazley, Entain Aug 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Ashtead Group, Beazley and Entain, on Friday. HIGHLIGHTS * Ashtead Group Plc AHT.L : KeyBanc initiates coverage with sector weight rating * Beazley Plc BEZG.L : Berenberg raises target price to 950p from 880p * Entain Plc ENT.L : Deutsche Bank cuts target price to 958p from 1,089p * Rheinmetall AG RHMG.DE : Morgan Stanley up
A
A
A
A
B
B
B
C
C
D
D
E
G
G
H
H
H
I
K
O
B

London's FTSE 100 ends lower as top companies trade ex-dividend

UPDATE 1-London's FTSE 100 ends lower as top companies trade ex-dividend For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window FTSE 100, FTSE 250 down 0.3% Heavyweights trade without dividend entitlement Beazley upgrades 2024 combined ratio forecast, shares surge Updated at 1425 GMT By Purvi Agarwal and Shubham Batra Aug 8 (Reuters) - London's FTSE 100 slipped on Thursday, tracking global market sentiment, while investors assessed corporate up
A
B
H
S
U

STOXX 600 recovers early losses on US jobs data relief

UPDATE 2-STOXX 600 recovers early losses on US jobs data relief For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Novo rebounds on positive read-across from Lilly Siemens jumps after profit beat Allianz rises on Q2 beat Deutsche Telekom up after increase in Q2 core earnings STOXX 600 up 0.1% Updates at 1600 GMT By Ankika Biswas and Pranav Kashyap Aug 8 (Reuters) - Europe's benchmark stock index recouped early losses to close slightly highe
B
D
H
P
S
S
S
A
Z
E
F
U
G

That unwind feeling

LIVE MARKETS-That unwind feeling STOXX 600 down 1.1% Volatility above 23 Banks, tech down Some UK earnings please Nasdaq futures fall Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com THAT UNWIND FEELING European shares got off to a lower start on Thursday, bringing about the feeling that the yen carry trade unwind is not over yet.
B
D
H
P
E
F
U
G

UK's Hikma gains on upbeat annual outlook, sturdy H1 performance

BUZZ-UK's Hikma gains on upbeat annual outlook, sturdy H1 performance ** Shares of British drugmaker Hikma Pharmaceuticals HIK.L up 5.3% at 1,937p ** Stock among top gainers in the FTSE 100 index .FTSE ** Co forecasts its annual revenue to grow in the range of 6% to 8%, up from previous outlook of 4% to 6% ** Sees FY core operating profit of $700 m
H
U

Hikma Sees FY Group Core Oper Profit Of $700 Mln To $730 Mln

BRIEF-Hikma Sees FY Group Core Oper Profit Of $700 Mln To $730 Mln Aug 8 (Reuters) - Hikma Pharmaceuticals PLC HIK.L : HY INTERIM DIVIDEND OF 32 CENTS PER SHARE, UP 28% UPGRADES GROUP GUIDANCE SEES FY GROUP REVENUE GROWTH OF 6% TO 8%, UP FROM 4% TO 6% SEES FY GROUP CORE OPERATING PROFIT OF $700 MILLION TO $730 MILLION, UP FROM $660 MILLION TO $700
H

UK Stocks-Factors to watch on August 8

UK Stocks-Factors to watch on August 8 Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.5%. * GSK: The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
A
A
B
B
B
D
F
G
H
I
I
L
P
P
P
R
S
S
U

NZ's AFT Pharmaceuticals gains on deal to distribute pain management tablets in US

BUZZ-NZ's AFT Pharmaceuticals gains on deal to distribute pain management tablets in US ** Shares of AFT Pharmaceuticals AFT.NZ rise as much as 1.6% to NZ$3.15, their highest level since June 18 ** Pharmaceutical co signs agreement with Hikma Pharmaceuticals USA to distribute its patented COMBOGESIC tablets, used for adult pain management, to selec
H

UK corporate earnings week ahead

DIARY-UK corporate earnings week ahead Aug 2 (Reuters) - Diary of U.K (.FTSE) corporate earnings for the week ahead UK EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 06-Aug-2024 06:00 IHG.L InterContinental Hotels Group PLC Half Year 2024 InterContinental Hotels Group PLC Earnings Release 07-Aug-2024 06:00 GLEN.L Glencore PLC Half Year 2024 Glencore PLC Earnings Release 07-Aug-2024 06:00 CCH.L Coca Cola HBC AG Half Year 2024 Coca Cola HBC AG Earnings Release 08-Aug-2024 NTS HIK
B
G
H
H
P
U

Hikma Pharmaceuticals Extends Voluntary Nationwide Recall Of One Lot Of Acetaminophen Injection, US FDA Says

BRIEF-Hikma Pharmaceuticals Extends Voluntary Nationwide Recall Of One Lot Of Acetaminophen Injection, US FDA Says July 22 (Reuters) - Food and Drug Administration: FDA: HIKMA PHARMACEUTICALS USA INC. EXTENDS VOLUNTARY NATIONWIDE RECALL OF ONE LOT OF ACETAMINOPHEN INJECTION, 1000MG/100ML, (10MG/ML) BAGS FDA-HIKMA RECALL DUE TO INDIVIDUAL UNIT OF AC
H

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

UPDATE 2-Teva launches generic version of Novo Nordisk's diabetes drug Victoza Adds details on Victoza in paragraphs 4 to 6 June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it had launched a generic version of Novo Nordisk's NOVOb.CO Victoza to treat patients with type 2 diabetes, making it the first generic GLP-1 drug in the United States where the drug class has seen overwhelming demand .
H
T

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

Teva launches generic version of Novo Nordisk's diabetes drug Victoza June 24 (Reuters) - Teva Pharmaceuticals TEVA.TA said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's NOVOb.CO drug Victoza to treat patients with type 2 diabetes. The U.S. Food and Drug Administration on Friday tentatively approved London-based Hikma Pharmaceuticals' HIK.L version of Victoza, according to the agency's website.
H
T

Hikma Acquires Xellia’S Assets

BRIEF-Hikma Acquires Xellia’S Assets June 17 (Reuters) - Hikma Pharmaceuticals PLC HIK.L : HIKMA PHARMACEUTICAL - HIKMA ACQUIRES XELLIA’S ASSETS HIKMA: HIKMA WILL PAY A CASH CONSIDERATION OF $135 MILLION, AND AN ADDITIONAL CONTINGENT CONSIDERATION OF UP TO $50 MILLION HIKMA: ACQUISITION WILL ADD EIGHT APPROVED AND MARKETED INJECTABLE PRODUCTS T
H

UK's Hikma gains as Citi raises target price

BUZZ-UK's Hikma gains as Citi raises target price ** Shares of British drugmaker Hikma Pharmaceuticals HIK.L up 3% at 1,989p ** Stock is top pct gainer on FTSE 100 index .FTSE ** Brokerage Citigroup raises target price to 2845p from 2770p ** Research firm IQVIA's data on HIK highly encouraging; we go to the top-end of forecast range - Citi ** Hikma
H
U
I

Banco Bpm, Firstgroup, Xps Pensions

EUROPE RESEARCH ROUNDUP-Banco Bpm, Firstgroup, Xps Pensions June 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Banco Bpm, Firstgroup and Xps Pensions Group, on Tuesday. HIGHLIGHTS * Banco Bpm BAMI.MI : Morgan Stanley cuts to equal weight from overweight * Firstgroup Plc FGP.L : RBC raises target price to 200p from 195p * JCDecaux SE JCDX.PA : Deutsche Bank cuts to hold from buy * Next Plc NXT.L : HSBC raises target price to 9,
B
B
C
C
D
E
E
E
E
F
H
H
H
I
K
M
N
N
S
S
U
U
H
A
B
I



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔